[Pubmed] Complications and Occurrence of Exacerbations in Patients with Myasthenia Gravis Treated with Oral Corticostero
Posté : 08 juil. 2026 12:00
Drugs Real World Outcomes. 2026 Jul 8. doi: 10.1007/s40801-026-00565-7. Online ahead of print.
ABSTRACT
BACKGROUND: Myasthenia gravis is a rare disease characterized by autoantibody-driven impairment of neuromuscular junction activity. Standard-of-care therapy includes oral corticosteroids (OCS), despite associated complications. This study describes OCS-related complications and exacerbations in a real-world myasthenia gravis population.
METHODS: This retrospective longitudinal cohort study leveraged US claims data (January 2016-March 2023; Optum's de-identified Clinformatics® Data Mart Database) to identify patients with myasthenia gravis (International Classification of Diseases, Tenth Revision, Clinical Modification: G70.00/01). Patients were classified into non-OCS and OCS cohorts; the OCS cohort was further stratified into < 6-month, 6-month, and 12-month exposure groups (≥ 5 mg/day prednisone-equivalent; 12-month follow-up). Inverse probability treatment weighting balanced baseline characteristics. Weighted prevalence ratios of select complications (e.g., diabetes, fracture, hyperlipidemia, hypertension, infection, myocardial infarction, osteoporosis, stroke, glaucoma) and rate/risk ratios for exacerbations were calculated.
RESULTS: The weighted population included 3297 patients in the non-OCS cohort and 418, 872, and 1243 patients in the < 6-month, 6-month, and 12-month OCS exposure groups, respectively. During follow-up, the < 6-month, 6-month, and 12-month OCS exposure groups had significantly higher infection risk versus non-OCS: weighted prevalence ratios (95% confidence interval) 1.6 (1.1-2.1), 1.5 (1.2-2.0), and 1.6 (1.3-2.0), respectively. Osteoporosis risk was similar in the < 6-month group but higher in the 6- and 12-month groups versus non-OCS: weighted prevalence ratios (95% confidence interval) 1.2 (0.9-1.6), 1.5 (1.2-1.8), and 1.7 (1.4-2.0), respectively. Oral corticosteroid exposure groups had more myasthenia gravis exacerbations during follow-up versus non-OCS.
CONCLUSIONS: After adjusting for observable confounders, OCS exposure within the 12-month initiation period was associated with a higher burden of complications and exacerbations among patients with myasthenia gravis.
PMID:42420579 | DOI:10.1007/s40801-026-00565-7
Source: https://pubmed.ncbi.nlm.nih.gov/4242057 ... 5&v=2.20.0